ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Core Insights - ImmunityBio, Inc. has provided an update on the enrollment status of its randomized registrational trial for BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005, indicating that enrollment has exceeded internal expectations and is over 85% complete [1] Enrollment Status - The trial's enrollment is anticipated to reach full capacity by Q2 2026, based on the current enrollment trajectory [1] - The company expects to submit a biologics license application following the completion of the trial [1]